CoChat

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer

Open access
Barault, Ludovic, Amatu, Alessio, Siravegna, Giulia, Ponzetti, Agostino, Moran, Sebastian, Cassingena, Andrea, Mussolin, Benedetta, Falcomatà, Chiara, Binder, Alexandra M, Cristiano, Carmen, Oddo, Daniele, Guarrera, Simonetta, Cancelliere, Carlotta, Bustreo, Sara, Bencardino, Katia, Maden, Sean, Vanzati, Alice, Zavattari, Patrizia, Matullo, Giuseppe, Truini, Mauro, Grady, William M, Racca, Patrizia, Michels, Karin B, Siena, Salvatore, Esteller, Manel, Bardelli, Alberto, Sartore-Bianchi, Andrea, Di Nicolantonio, Federica · 2018 · Gut
Cited by 234

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Objective: Mutations in cell-free circulating DNA (cfDNA) have been studied for tracking disease relapse in colorectal cancer (CRC). This approach requires personalised assay design due to the lack of universally mutated genes. In contrast, early methylation alterations are restricted to defined genomic loci allowing comprehensive assay design for population studies. Our objective was to identify cancer-specific methylated biomarkers which could be measured longitudinally in cfDNA (liquid biopsy) to monitor therapeutic outcome in patients with metastatic CRC (mCRC). Design: Genome-wide methylation microarrays of CRC cell lines (n=149) identified five cancer-specific methylated loci (EYA4, GRIA4, ITGA4, MAP3K14-AS1, MSC). Digital PCR assays were employed to measure methylation of these genes in tumour tissue DNA (n=82) and cfDNA from patients with mCRC (n=182). Plasma longitudinal assessment was performed in a patient subset treated with chemotherapy or targeted therapy. Results: Methylation in at least one marker was detected in all tumour tissue samples and in 156 mCRC patient cfDNA samples (85.7%). Plasma marker prevalence was 71.4% for EYA4, 68.5% for GRIA4, 69.7% for ITGA4, 69.1% for MAP3K14-AS1% and 65.1% for MSC. Dynamics of methylation markers was not affected by treatment type and correlated with objective tumour response and progression-free survival. Conclusion: This five-gene methylation panel can be used to circumvent the absence of patient-specific mutations for monitoring tumour burden dynamics in liquid biopsy under different therapeutic regimens. This method might be proposed for assessing pharmacodynamics in clinical trials or when conventional imaging has limitations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2016-313372

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 234

Metadata

Authors
Barault, L., Amatu, A., Siravegna, G., Ponzetti, A., Moran, S., Cassingena, A., Mussolin, B., Falcomatà, C., Binder, A. M., Cristiano, C., Oddo, D., Guarrera, S., Cancelliere, C., Bustreo, S., Bencardino, K., Maden, S., Vanzati, A., Zavattari, P., Matullo, G., Truini, M., Grady, W. M., Racca, P., Michels, K. B., Siena, S., Esteller, M., Bardelli, A., Sartore-Bianchi, A., & Di Nicolantonio, F.
Venue
Gut
Publisher
BMJ
Published
2017-10-05
Volume
67
Issue
11
Pages
1995-2005
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2760986701
Cited by
234
References
12
FWCI
6.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.